Breaking Down Ezaki Glico Co., Ltd. Financial Health: Key Insights for Investors

Dive into a data-driven look at Ezaki Glico Co., Ltd. (2206.T): the quarter to Sept 30, 2025 posted revenue of ¥100.24 billion (up 15.03% year-over-year) and TTM revenue of ¥354.70 billion (up 8.40% YoY), yet fiscal 2024 net income slipped to ¥8.11 billion - a 42.60% drop - even as gross profit margin held at 38.54%; the balance sheet shows ¥56.6 billion in cash vs. a mere ¥165 million of debt, market cap sits at ¥345.37 billion with a share price of ¥5,425.00 (12/12/2025), valuation metrics include a trailing P/E of 48.20 and forward P/E of 32.71, P/B of 1.27 and P/S of 0.97, while analysts place a consensus 'Moderate Sell' with an average target of ¥3,199.65 (a 36.03% downside) amid headwinds from a chocolate recall, weaker ice cream/chilled sales and falling operating cash flow that has produced negative free cash flow-read on to see how these figures shape investment risks and growth levers such as international expansion, health-focused innovation and expected ~8% revenue growth through 2025.

Ezaki Glico Co., Ltd. (2206.T) - Revenue Analysis

Ezaki Glico reported solid top-line growth in the quarter ending September 30, 2025, alongside multi-year trends and productivity metrics that help frame valuation and operational efficiency.

• Quarter (Sep 30, 2025): Revenue ¥100.24 billion - +15.03% year-over-year.
• Trailing Twelve Months (TTM) Revenue: ¥354.70 billion - +8.40% YoY.
• Fiscal 2024 Annual Revenue: ¥331.13 billion - -0.44% vs prior year.
• Revenue per employee: ~¥63.76 million (5,563 employees).
• Price-to-Sales (P/S) ratio: 0.97.
• Market capitalization: ¥345.37 billion; Share price: ¥5,425.00 (as of Dec 12, 2025).

Key implications for investors:

• Recent quarter strength (+15.03% YoY) suggests improving demand or pricing leverage versus the modest annual decline in 2024.
• TTM growth (8.40%) indicates recovery and expansion driven over the past year.
• P/S of 0.97 positions the market valuation near one times sales - a moderate multiple for a consumer staples / food manufacturer with stable margins.
• Revenue per employee (~¥63.76M) reflects operational productivity; compare with peers for context.

For broader context on the company's strategic positioning, history, and business model see: Ezaki Glico Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Ezaki Glico Co., Ltd. (2206.T) - Profitability Metrics

• Net income (FY2024): ¥8.11 billion - down 42.60% year-over-year.
• Net profit margin (FY2024): 2.45% (FY2023: 4.25%) - lower conversion of revenue into net profit.
• EBIT margin: declined in 2024 versus 2023, signaling pressure on operating profitability.
• EPS (FY2024): ¥127.52 - decreased from the prior year.
• Return on equity (ROE FY2024): 2.98% (FY2023: 5.38%) - less efficient use of equity capital.
• Gross profit margin (FY2024): 38.54% - remains strong, reflecting effective cost management at the gross level.

• Primary drivers: revenue/volume dynamics, cost of sales control (supports gross margin), and rising operating costs or one-off items that compressed EBIT and net margins.
• Investor focus areas: trend in operating expenses and SG&A, trajectory of EBIT margin recovery, and sustainability of the 38.54% gross margin.
• Valuation/earnings perspective: lower EPS and ROE reduce near-term return expectations; monitor upcoming quarters for margin stabilization or recovery.

Ezaki Glico Co., Ltd. (2206.T) - Debt vs. Equity Structure

• Equity ratio: 72.00% (2024), indicating a predominantly equity-funded balance sheet.
• Debt-to-equity ratio: 0.61% (2024), showing minimal reliance on debt financing.
• Total reported interest-bearing debt: ¥165 million (very low absolute debt level).
• Cash and cash equivalents: ¥56.6 billion, providing substantial liquidity versus negligible debt.
• Return on equity (ROE): 2.98% in 2024, down from 5.38% in 2023, signaling reduced efficiency in generating returns on equity.

• Strategic flexibility: low debt and large cash reserves create capacity for acquisitions, R&D, capital spending, or increased dividends/share buybacks.
• Risk profile: conservative leverage reduces financial risk from interest-rate or cash-flow shocks.
• Performance signal: declining ROE warrants monitoring-could reflect margin pressure, lower net income, or higher equity base outpacing earnings.

Ezaki Glico Co., Ltd. (2206.T) - Liquidity and Solvency

• Cash & short-term investments (June 2025): ¥51.84 billion (-15.64% YoY)
• Total assets (June 2025): ¥369.01 billion (-0.86% YoY)
• Total liabilities (June 2025): ¥102.37 billion (+4.63% YoY)
• Reported interest-bearing debt: ¥0.165 billion (¥165 million) - very low absolute debt level
• Operating cash flow: materially decreased year-over-year, producing negative free cash flow
• Current ratio / quick ratio: not specified in available disclosures

• Balance-sheet strength: low interest-bearing debt (¥165 million) indicates conservative leverage and room to absorb shocks without large financing stress.
• Liquidity concerns: a 15.64% drop in cash and short-term investments reduces the immediate liquidity cushion despite sizeable absolute cash holdings (¥51.84 billion).
• Liability dynamics: total liabilities increased 4.63% while assets contracted slightly, modestly compressing net asset buffer.
• Cash-flow pressure: significant decline in operating cash flow and resulting negative free cash flow are the most critical red flags for long-term financial sustainability and capital return capacity.
• Missing ratios: absence of published current and quick ratios limits quick benchmark comparisons; investors should compute working-capital metrics from full financial statements or request the latest disclosures.

Ezaki Glico Co., Ltd. (2206.T) - Valuation Analysis

Key market and valuation metrics for Ezaki Glico Co., Ltd. (2206.T) present a picture of premium earnings valuation, modest market-to-book pricing, and conservative leverage that supports optionality for capital allocation.

• High trailing P/E (48.20) indicates the market is pricing significant historical growth or a quality premium into current earnings.
• Forward P/E (32.71) shows expected earnings improvement relative to trailing results, narrowing the valuation multiple.
• P/B of 1.27 signals modest premium to book value - investors are paying above net assets but not at extreme premium levels.
• EV of ¥293.75 billion vs. market cap of ¥345.37 billion reflects net cash or low net debt position embedded in enterprise valuation.
• Dividend yield of 1.84% combined with an upcoming ex-dividend date (2025-12-29) offers income but not a primary return driver.
• Low debt provides flexibility for acquisitions, capex, or sustained dividends without high interest burden.

For additional context on ownership, investor behavior and deeper company profile, see: Exploring Ezaki Glico Co., Ltd. Investor Profile: Who's Buying and Why?

Ezaki Glico Co., Ltd. (2206.T) - Risk Factors

• Regulatory & compliance risk: food safety standards, labeling and health-claim regulations in Japan and export markets remain critical. Non-compliance can trigger recalls, fines and reputational damage.
• Competitive pressure: intense rivalry from domestic players (e.g., Meiji Holdings) and international snack and confectionery brands threatens market share and pricing power.
• Input-cost volatility: fluctuations in sugar, dairy and other commodity prices can compress margins; historically the company has used sourcing strategies and pricing actions to mitigate impact.
• Supply-chain disruptions: logistics or geopolitical issues in export markets can interrupt production/distribution-no major operational disruptions have been publicly reported recently.
• Operational incidents: product recalls can force downward revisions to guidance and dent consumer confidence; a recent chocolate recall contributed to a revised FY2025 forecast and ongoing weakness in ice cream and chilled-product sales.
• Market sentiment / analyst outlook: consensus analyst rating of "Moderate Sell" and a sizable gap between current share price and analyst target can amplify downside risk if sentiment worsens.

• Analyst view & valuation: the analyst consensus target is ¥3,199.65, representing a 36.03% decline versus the implied current share price (~¥5,002). This gap highlights near-term downside risk driven by operational setbacks (recalls) and soft demand in ice cream/chilled categories.
• What to watch next: updates to FY2025 guidance, recall resolution and remediation costs, commodity cost trends (sugar/dairy/cocoa), quarterly sales in ice cream/chilled segments, and any regulatory developments in key export markets.

Ezaki Glico Co., Ltd. (2206.T) - Growth Opportunities

Ezaki Glico is positioning itself to convert brand strength and product innovation into sustainable top-line expansion, with a particular emphasis on Southeast Asia, health-oriented SKUs, and seasonal marketing. Management guidance and analyst models point to continued growth driven by both domestic resilience and faster international expansion.

• Analysts project revenue growth of ~8% year-over-year through 2025, supported by new product releases and increased international penetration.
• Management targets Southeast Asia as the primary geographic expansion area, emphasizing localized flavors, pricing, and trade marketing.
• Health & wellness SKUs (reduced sugar, high-protein, functional ingredients) are prioritized to capture premium and health-conscious segments.

• Southeast Asia opportunity: rising per-capita snacking spend, modern trade expansion, and e-commerce penetration support a target CAGR in the region of 9-12% over the next 3 years.
• Product innovation cadence: seasonal Pocky variants (holiday flavors, limited editions) plus new health-focused launches are expected to lift unit prices and frequency of purchase.
• Channel mix optimization: accelerated D2C and e-commerce sales complement export growth to reduce reliance on domestic convenience-store channels.

Key operational levers and expected impacts:

• Localization (pack size, flavor, promotional calendar): improves market fit and shortens payback on marketing spend-targeting 3-6 months payback for pilot SKUs in SEA markets.
• Health/wellness R&D: expanding reformulation and functional snack lines to capture premium margins (gross-margin improvement of ~100-200 bps targeted on health SKUs).
• Seasonal campaigns: limited editions and cross-promotions aim to increase Q4 sales by mid-single-digit percentage points versus prior-year quarters.

Market dynamics and risks to realize these opportunities:

• Currency exposure: yen appreciation versus ASEAN currencies can compress reported international revenue-management uses hedging and local sourcing to mitigate.
• Commodity cost volatility: cocoa, dairy, and palm oil price swings can impact COGS; margin resiliency depends on pricing power and SKU mix.
• Competitive intensity: global snack incumbents and nimble local brands require differentiated innovation and stronger trade execution.

Capital allocation and growth funding: management has signaled continued reinvestment of operating cash flow into marketing, capex for manufacturing scale in Southeast Asia, and selective M&A to accelerate localization.

For more background on shareholder composition and investor interest that may influence strategic flexibility, see: Exploring Ezaki Glico Co., Ltd. Investor Profile: Who's Buying and Why?